{"downloaded": true, "htmlmade": false, "full": {"id": "29603842", "source": "MED", "pmid": "29603842", "pmcid": "PMC6033152", "fullTextIdList": {"fullTextId": "PMC6033152"}, "doi": "10.1111/jns.12267", "title": "A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.", "authorString": "Cornblath DR, Hartung HP, Katzberg HD, Merkies ISJ, van Doorn PA.", "authorList": {"author": [{"fullName": "Cornblath DR", "firstName": "David R", "lastName": "Cornblath", "initials": "DR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland."}}}, {"fullName": "Hartung HP", "firstName": "Hans-Peter", "lastName": "Hartung", "initials": "HP", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Neurology, Medical Faculty, Heinrich Heine University, D\u00fcsseldorf, Germany."}}}, {"fullName": "Katzberg HD", "firstName": "Hans D", "lastName": "Katzberg", "initials": "HD", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Neurology, University of Toronto, Toronto General Hospital/UHN, Toronto, Ontario, Canada."}}}, {"fullName": "Merkies ISJ", "firstName": "Ingemar S J", "lastName": "Merkies", "initials": "ISJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands."}}}, {"fullName": "van Doorn PA", "firstName": "Pieter A", "lastName": "van Doorn", "initials": "PA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands."}}}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "2", "volume": "23", "journalIssueId": "2697220", "dateOfPublication": "2018 Jun", "monthOfPublication": "6", "yearOfPublication": "2018", "printPublicationDate": "2018-06-01", "journal": {"title": "Journal of the peripheral nervous system : JPNS", "ISOAbbreviation": "J Peripher Nerv Syst", "medlineAbbreviation": "J Peripher Nerv Syst", "NLMid": "9704532", "ISSN": "1085-9489", "ESSN": "1529-8027"}}, "pubYear": "2018", "pageInfo": "108-114", "abstractText": "Patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) show varying degrees of response to intravenous immunoglobulin (IVIg) therapy. This randomised phase III study in patients with CIDP (ProCID trial) will compare the efficacy and safety of 3 different doses (0.5, 1.0, and 2.0 g/kg) of IVIg 10% (panzyga) administered every 3 weeks for 24\u2009weeks. The primary efficacy endpoint is the rate of treatment response, defined as a decrease in adjusted inflammatory neuropathy cause and treatment disability score of \u22651 point, in the IVIg 1.0 g/kg arm at week 24. Patients with definite or probable CIDP according to European Federation of Neurological Sciences/Peripheral Nerve Society criteria with IVIg or corticosteroid dependency and active disease are eligible. All potentially eligible patients will undergo IVIg or corticosteroid dose reduction (washout phase) over \u226412\u2009weeks or until deterioration of CIDP (active disease). Patients with deterioration during the washout phase will be randomised to receive study treatment during a dose-evaluation phase starting with a loading dose of IVIg 2.0 g/kg followed by maintenance treatment with IVIg 0.5, 1.0, or 2.0 g/kg every 3 weeks. Rescue medication (2 doses of IVIg 2.0 g/kg given 3 weeks apart) will be administered to patients in the IVIg 0.5 and 1.0 g/kg groups who deteriorate after week 3 and before week 18 or who do not improve at week 6. Safety, tolerability and quality of life will be assessed. The ProCID study will provide new information on the best maintenance dose of IVIg for patients with CIDP.", "affiliation": "Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase III", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating", "meshQualifierList": {"meshQualifier": {"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Immunoglobulins, Intravenous", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Disability Evaluation"}, {"majorTopic_YN": "N", "descriptorName": "Treatment Outcome"}, {"majorTopic_YN": "N", "descriptorName": "Clinical Protocols"}, {"majorTopic_YN": "N", "descriptorName": "Double-Blind Method"}, {"majorTopic_YN": "N", "descriptorName": "Dose-Response Relationship, Drug"}, {"majorTopic_YN": "N", "descriptorName": "Research Design"}, {"majorTopic_YN": "N", "descriptorName": "Quality of Life"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}]}, "keywordList": {"keyword": ["intravenous immunoglobulin", "Study Design", "Chronic Inflammatory Demyelinating Polyradiculoneuropathy", "Randomised-controlled Trial", "Trial Protocol"]}, "chemicalList": {"chemical": {"name": "Immunoglobulins, Intravenous", "registryNumber": "0"}}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1111/jns.12267"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6033152"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6033152?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "3", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-10-25", "dateOfCreation": "2018-04-01", "firstIndexDate": "2018-04-01", "fullTextReceivedDate": "2020-07-09", "dateOfRevision": "2021-01-09", "electronicPublicationDate": "2018-04-26", "firstPublicationDate": "2018-04-26"}, "htmllinks": "https://europepmc.org/articles/PMC6033152", "abstract": "Patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) show varying degrees of response to intravenous immunoglobulin (IVIg) therapy. This randomised phase III study in patients with CIDP (ProCID trial) will compare the efficacy and safety of 3 different doses (0.5, 1.0, and 2.0 g/kg) of IVIg 10% (panzyga) administered every 3 weeks for 24\u2009weeks. The primary efficacy endpoint is the rate of treatment response, defined as a decrease in adjusted inflammatory neuropathy cause and treatment disability score of \u22651 point, in the IVIg 1.0 g/kg arm at week 24. Patients with definite or probable CIDP according to European Federation of Neurological Sciences/Peripheral Nerve Society criteria with IVIg or corticosteroid dependency and active disease are eligible. All potentially eligible patients will undergo IVIg or corticosteroid dose reduction (washout phase) over \u226412\u2009weeks or until deterioration of CIDP (active disease). Patients with deterioration during the washout phase will be randomised to receive study treatment during a dose-evaluation phase starting with a loading dose of IVIg 2.0 g/kg followed by maintenance treatment with IVIg 0.5, 1.0, or 2.0 g/kg every 3 weeks. Rescue medication (2 doses of IVIg 2.0 g/kg given 3 weeks apart) will be administered to patients in the IVIg 0.5 and 1.0 g/kg groups who deteriorate after week 3 and before week 18 or who do not improve at week 6. Safety, tolerability and quality of life will be assessed. The ProCID study will provide new information on the best maintenance dose of IVIg for patients with CIDP.", "Keywords": ["intravenous immunoglobulin", "Study Design", "Chronic Inflammatory Demyelinating Polyradiculoneuropathy", "Randomised-controlled Trial", "Trial Protocol"], "pdflinks": "https://europepmc.org/articles/PMC6033152?pdf=render", "journaltitle": "Journal of the peripheral nervous system : JPNS", "authorinfo": ["Cornblath DR", "Hartung HP", "Katzberg HD", "Merkies ISJ", "van Doorn PA"], "title": "A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol."}